In the Original Contribution entitled "Bivalirudin and Provisional Glycoprotein
IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa
Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial"
published in the February 19, 2003, issue of THE JOURNAL (2003;289:853-863),
there was incorrect wording on 3 pages. On page 855 in Figure 1, the box indicating
the number of patients assigned to receive bivalirudin should have read "2910
Received Bivalirudin" and "2 Received Heparin Plus Glycoprotein IIb/IIIa."
On page 859 in Table 3, the footnote symbols for the P values
comparing Q-wave and non–Q-wave myocardial infarction (MI) and for CK-MB
values should have been double daggers, indicating that the P values are "for trends in MI type or CK-MB elevation." The footnote
symbol in the "Major bleeding" row of the "Heparin Plus Glycoprotein IIb/IIIa"
column should have been a single dagger, indicating that "complete data were
available for 2990, but bleeding data were available for 1 additional patient
who reached the end point of the quadruple composite," and the footnote symbol
in the same row but in the "Bivalirudin" column should have been deleted.
On page 857, the percentage in parentheses that read "2.49% vs 4.1%" should
have read "2.4% vs 4.1."